Mantle cell lymphoma

MCL · Oncology · 4 drugs · 2 indications

Aggressive B-cell lymphoma with cyclin D1 overexpression.
Competitive Landscape (4 drugs)
DrugCompanyMechanismModalityRouteStage
CalquenceAZNBTK inhibitorSmall moleculeORALAPPROVED
JaypircaLLYBTK inhibitor (non-covalent)Small moleculeORALAPPROVED
TecartusGILDCD19 CAR-TCell therapyIVAPPROVED
ImbruvicaABBVBTK inhibitorSmall moleculePOAPPROVED
Indications (2)
r/r MCL
Tecartus APPROVEDImbruvica APPROVED
Mantle cell lymphoma
Calquence APPROVEDJaypirca APPROVED
Upcoming Catalysts
Pirtobrutinib - 1L MCL - FDA FilingREGULATORY
LLY2026
Pirtobrutinib - CLL - Ph3 - Full Data vs ImbruvicaCLINICAL
LLYH1 2026
Data from Supabase · Updated 2026-03-24